Clinical Trials / Research Studies
Low Grade Glioma Relapse / Refractory

Low Grade Glioma Relapse / Refractory

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

  • Ages: 0 Years to 21 Years

The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adul ...More

APEC1621: Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders

  • Ages: 12 Months to 21 Years

PURPOSE: This screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/o ...More

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

  • Ages: 6 Months to 18 Years

This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors. In this study, we will test the combination of atezolizumab with chemotherap ...More

Contact Us

Contact us.

To learn more about available clinical trials related to brain and spinal tumors, contact us at cancer@cchmc.org or 513-636-2799.

Related Studies

Give Today

3333 Burnet Avenue, Cincinnati, Ohio 45229-3026

© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.

U.S. News & World Report Honor Roll Badge for Top Children's Hospital.Best Places to Work.America's Best Large Employers